| European Case Law Identifier: | ECLI:EP:BA:2012:T154508.20120321 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 21 March 2012 | ||||||||
| Case number: | T 1545/08 | ||||||||
| Application number: | 99303729.0 | ||||||||
| IPC class: | A61K 38/21 A61K 31/7056 A61P 31/14 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | C | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection | ||||||||
| Applicant name: | Merck Sharp & Dohme Corp. | ||||||||
| Opponent name: | Alfa Wassermann S.p.A. Teva Pharmaceutical Industries Ltd. Sandoz GmbH Krauss, Jan B. Forrester & Boehmert |
||||||||
| Board: | 3.3.04 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Inventive step - (yes) | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t081545eu1.html
Date retrieved: 17 May 2021